| Samantha Curley, CRC | |
|
1354 Hancock St Ste 209, Quincy, MA 02169-5109 | |
| (617) 471-5686 | |
| Not Available |
| Full Name | Samantha Curley |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 1354 Hancock St Ste 209, Quincy, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023732922 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Curley, CRC 1354 Hancock St Ste 209, Quincy, MA 02169-5109 Ph: (617) 471-5686 | Samantha Curley, CRC 1354 Hancock St Ste 209, Quincy, MA 02169-5109 Ph: (617) 471-5686 |
News Archive
A small area in the midbrain known as the substantia nigra is the control center for all bodily movement. Increasing loss of dopamine-generating neurons in this part of the brain therefore leads to the main symptoms of Parkinson's disease - slowness of movement, rigidity and shaking.
University Hospitals Seidman Cancer Center is breaking ground today on a $30 million proton therapy center, becoming one of an elite group of cancer centers in the country to offer this revolutionary technology. There are currently only 11 operational proton therapy centers in the nation and the UH Seidman Cancer Center site will be the first in Ohio.
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.
Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
› Verified 6 days ago
Karia Higginbottom, Counselor Medicare: Not Enrolled in Medicare Practice Location: 460 Quincy Ave, Quincy, MA 02169 Phone: 617-847-1950 | |
Ethan Zachary Stein, Counselor Medicare: Not Enrolled in Medicare Practice Location: 460 Quincy Ave, Quincy, MA 02169 Phone: 978-387-9023 | |
Steven James Gibbons, RECOVERY COACH Counselor Medicare: Not Enrolled in Medicare Practice Location: 85 Quincy Ave Ste B, Quincy, MA 02169 Phone: 857-939-1363 | |
Mr. Tom F Chappuis Jr., Counselor Medicare: Not Enrolled in Medicare Practice Location: 460 Quincy Ave, Quincy, MA 02169 Phone: 617-774-6036 | |
Ms. Anke C Thorne, MS LMHC Counselor Medicare: Medicare Enrolled Practice Location: 1 Billings Rd Ste 306, Quincy, MA 02171 Phone: 617-314-3495 Fax: 781-826-0012 | |
Daniel Robert Maltais, M.ED. Counselor Medicare: Not Enrolled in Medicare Practice Location: 13 Temple St, Quincy, MA 02169 Phone: 617-471-8400 | |
Mr. Christopher C Coan, BA Counselor Medicare: Not Enrolled in Medicare Practice Location: 13 Temple St, Quincy, MA 02169 Phone: 617-471-8400 |